Sustained PFS benefit in breast cancer with palbociclib + exemestane with ovarian function suppression
Treatment with palbociclib plus exemestane with ovarian function suppression does not appear to produce improvements in overall survival (OS), although it yields sustained increases in progression-free survival (PFS) as compared with capecitabine in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer, according to updated data from the phase II Young-PEARL study.
